Literature DB >> 11986244

Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.

Massimo Di Nicola1, Carmelo Carlo-Stella, Michele Magni, Marco Milanesi, Paolo D Longoni, Paola Matteucci, Salvatore Grisanti, Alessandro M Gianni.   

Abstract

CD2(+) T lymphocytes obtained from either the donor of bone marrow stromal cells (BMSCs) or a third party were cultured in mixed lymphocyte reactions (MLRs) with either allogeneic dendritic cells (DCs) or peripheral blood lymphocytes (PBLs). When autologous or allogeneic BMSCs were added back to T cells stimulated by DCs or PBLs, a significant and dose-dependent reduction of T-cell proliferation, ranging from 60% +/- 5% to 98% +/- 1%, was evident. Similarly, addition of BMSCs to T cells stimulated by polyclonal activators resulted in a 65% +/- 5% (P =.0001) suppression of proliferation. BMSC- induced T-cell suppression was still evident when BMSCs were added in culture as late as 5 days after starting of MLRs. BMSC-inhibited T lymphocytes were not apoptotic and efficiently proliferated on restimulation. BMSCs significantly suppressed both CD4(+) and CD8(+) T cells (65% +/- 5%, [P =.0005] and 75% +/- 15% [P =.0005], respectively). Transwell experiments, in which cell-cell contact between BMSCs and effector cells was prevented, resulted in a significant inhibition of T-lymphocyte proliferation, suggesting that soluble factors were involved in this phenomenon. By using neutralizing monoclonal antibodies, transforming growth factor beta1 and hepatocyte growth factor were identified as the mediators of BMSC effects. In conclusion, our data demonstrate that (1) autologous or allogeneic BMSCs strongly suppress T-lymphocyte proliferation, (2) this phenomenon that is triggered by both cellular as well as nonspecific mitogenic stimuli has no immunologic restriction, and (3) T-cell inhibition is not due to induction of apoptosis and is likely due to the production of soluble factors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986244     DOI: 10.1182/blood.v99.10.3838

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  960 in total

1.  Immune modulation of co-transplantation mesenchymal stem cells with islet on T and dendritic cells.

Authors:  F R Li; X G Wang; C Y Deng; H Qi; L L Ren; H X Zhou
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease.

Authors:  M Youd; C Blickarz; L Woodworth; T Touzjian; A Edling; J Tedstone; M Ruzek; R Tubo; J Kaplan; T Lodie
Journal:  Clin Exp Immunol       Date:  2010-04-29       Impact factor: 4.330

3.  Canine bone marrow-derived mesenchymal stromal cells suppress alloreactive lymphocyte proliferation in vitro but fail to enhance engraftment in canine bone marrow transplantation.

Authors:  Won Sik Lee; Yasuhiro Suzuki; Scott S Graves; Mineo Iwata; G M Venkataraman; Marco Mielcarek; Laura J Peterson; Susumu Ikehara; Beverly Torok-Storb; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-10       Impact factor: 5.742

4.  Human embryonic stem cell-derived mesenchymal stromal cells.

Authors:  Peiman Hematti
Journal:  Transfusion       Date:  2011-11       Impact factor: 3.157

5.  Materials-Directed Differentiation of Mesenchymal Stem Cells for Tissue Engineering and Regeneration.

Authors:  J Kent Leach; Jacklyn Whitehead
Journal:  ACS Biomater Sci Eng       Date:  2017-03-14

6.  Distinct Immunoregulatory Mechanisms in Mesenchymal Stem Cells: Role of the Cytokine Environment.

Authors:  Vladimir Holan; Barbora Hermankova; Pavla Bohacova; Jan Kossl; Milada Chudickova; Michaela Hajkova; Magdalena Krulova; Alena Zajicova; Eliska Javorkova
Journal:  Stem Cell Rev Rep       Date:  2016-12       Impact factor: 5.739

Review 7.  Mesenchymal stem cells in the treatment of spinal cord injuries: A review.

Authors:  Venkata Ramesh Dasari; Krishna Kumar Veeravalli; Dzung H Dinh
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

Review 8.  Mesenchymal stem cells in treating autism: Novel insights.

Authors:  Dario Siniscalco; James Jeffrey Bradstreet; Nataliia Sych; Nicola Antonucci
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

9.  Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells in vitro.

Authors:  Lauren V Schnabel; Christian M Abratte; John C Schimenti; M Julia Bevilaqua Felippe; Jennifer M Cassano; Teresa L Southard; Jessica A Cross; Lisa A Fortier
Journal:  Regen Med       Date:  2014-04-28       Impact factor: 3.806

10.  [Allogenic transplantation of human mesenchymal stem cells for tissue engineering purposes: an in vitro study].

Authors:  P Niemeyer; A Seckinger; H G Simank; P Kasten; N Südkamp; U Krause
Journal:  Orthopade       Date:  2004-12       Impact factor: 1.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.